Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Azelio in connection with a directed share issue of SEK 270 million
Mandate

Vinge has advised Azelio in connection with a directed share issue of SEK 270 million

September 10, 2020 Capital Markets and Public M&A

Vinge has advised Azelio, a public Swedish company specialising in thermal energy storage with dispatchable and low-cost Stirling-based electricity and heat production, in connection with a directed share issue whereby Azelio raises SEK 270 million in issue proceeds before transaction costs.

The subscription price was determined to SEK 22 per share through a so called accelerated bookbuilding procedure. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance the company’s ongoing operations and the continued industrialization of Azelio’s Thermal Energy Storage (TES) and Stirling-based electricity production technology, with the objective of reaching industrial volume production in 2021. Azelio’s shares are listed on Nasdaq First North Growth Market.

Vinge’s team consisted of David Andersson, William Kåge, Julia Hirschberg and Olof Löfvenberg.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026